" class="no-js "lang="en-US"> Indrajit Choudhuri - Medtech Alert
Thursday, October 09, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Indrajit Choudhuri

Indrajit Choudhuri

About Indrajit Choudhuri

Dr. Indrajit Choudhuri, MD is a Cardiology Specialist in Kenosha, WI. Dr. Choudhuri has extensive experience in Cardiac Electrical System Procedures. He is affiliated with Aurora Saint Lukes Medical Center, winner of the Coronary Intervention Excellence Award. He is also affiliated with Beloit Memorial Hospital. His office is not accepting new patients.

Related Story

Cardiovascular

 MediCardia Health Inc. Integrates Optimize EP C-aRM to Develop First of it's Kind

MediCardia Health Inc. Integrates Optimize EP C-aRM to Develop First of it's Kind, Comprehensive Connected Cardiac Care Platform

May 27 2022

MediCardia Health Inc., a pioneer in global digital health, announced today that the Company has […]